ranolazine

Generic: ranolazine

Labeler: ajanta pharma usa inc.
NDC Directory HUMAN PRESCRIPTION DRUG ANDA Inactive Finished

Drug Facts

Product Profile

Brand Name ranolazine
Generic Name ranolazine
Labeler ajanta pharma usa inc.
Dosage Form TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients

ranolazine 500 mg/1

Manufacturer
Ajanta Pharma USA Inc.

Identifiers & Regulatory

Product NDC 27241-125
Product ID 27241-125_933f695e-e4f4-4c75-80fc-aea9a30aa13d
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category ANDA
Application Number ANDA210054
Listing Expiration 2026-12-31
Marketing Start 2019-08-23

Pharmacologic Class

Established (EPC)
anti-anginal [epc]
Mechanism of Action
cytochrome p450 3a inhibitors [moa] p-glycoprotein inhibitors [moa] cytochrome p450 2d6 inhibitors [moa] organic cation transporter 2 inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 27241125
Hyphenated Format 27241-125

Supplemental Identifiers

RxCUI
616749 728231
UPC
0327241125027 0327241126024
UNII
A6IEZ5M406
NUI
N0000175427 N0000190114 N0000185503 N0000182137 N0000187061

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name ranolazine (source: ndc)
Generic Name ranolazine (source: ndc)
Application Number ANDA210054 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 500 mg/1
source: ndc
Packaging
  • 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-02)
  • 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-05)
source: ndc

Packages (2)

27241-125-02 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-02) 27241-125-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-05)

Ingredients (1)

ranolazine (500 mg/1)

Linked Drug Pages (1)

Ranolazine ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "933f695e-e4f4-4c75-80fc-aea9a30aa13d", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "upc": ["0327241125027", "0327241126024"], "unii": ["A6IEZ5M406"], "rxcui": ["616749", "728231"], "spl_set_id": ["8bfd1a61-547a-4847-ae4e-480b17da6272"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["Ajanta Pharma USA Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-02)", "package_ndc": "27241-125-02", "marketing_start_date": "20190823"}, {"sample": false, "description": "500 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-05)", "package_ndc": "27241-125-05", "marketing_start_date": "20210714"}], "brand_name": "Ranolazine", "product_id": "27241-125_933f695e-e4f4-4c75-80fc-aea9a30aa13d", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "27241-125", "generic_name": "Ranolazine", "labeler_name": "Ajanta Pharma USA Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Ranolazine", "active_ingredients": [{"name": "RANOLAZINE", "strength": "500 mg/1"}], "application_number": "ANDA210054", "marketing_category": "ANDA", "marketing_start_date": "20190823", "listing_expiration_date": "20261231"}